Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial for Patients With Glioblastoma Multiforme (GBM) Treated With Gliadel Followed by Avastin Plus Irinotecan

NCT00735436 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT00735436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00735436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial for Patients With Glioblastoma Multiforme (GBM) Treated With Gliadel Followed by Avastin Plus Irinotecan
Lead sponsor
Duke University
Phase
Phase 2
Overall status
Terminated
Start date
December 31, 2008
Completion date
October 31, 2012
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme, gliosarcoma, malignant glioma